

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6648587

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
RICHARD E. OLSON	11/06/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BRISTOL MYERS SQUIBB COMPANY
<b>Street Address:</b>	RT. 206 & PROVINCE LINE RD.
<b>City:</b>	PRINCETON
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08543
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17139161
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 428-0200
<b>Email:</b>	patentadmin@clarkelbing.com
<b>Correspondent Name:</b>	CLARK & ELBING LLP
<b>Address Line 1:</b>	101 FEDERAL STREET
<b>Address Line 2:</b>	15TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	51551.004003
<b>NAME OF SUBMITTER:</b>	THOMAS J. TAKARA, PH.D.
<b>SIGNATURE:</b>	/Thomas J. Takara, Ph.D./
<b>DATE SIGNED:</b>	04/08/2021
<b>Total Attachments: 4</b>	
source=34850 US1 Assignment BMS inventor Olson to BMS1 (62726005)#page1.tif	
source=34850 US1 Assignment BMS inventor Olson to BMS1 (62726005)#page2.tif	
source=34850 US1 Assignment BMS inventor Olson to BMS1 (62726005)#page3.tif	
source=34850 US1 Assignment BMS inventor Olson to BMS1 (62726005)#page4.tif	

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. PATENT APPLICATION NO. .... 62/726,005  
FILING DATE ..... August 31, 2018  
INVENTOR(S)..... Hagedorn et al.  
ASSIGNEE..... Bristol Myers Squibb Company  
ATTORNEY'S DOCKET NO ..... 103135.0239  
TITLE..... OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION

**PATENT ASSIGNMENT**

**Inventor:**

Richard E. Olson  
5 Research Parkway  
Wallingford, CT 06492  
*Citizenship: US*

**Assignee:**

Bristol Myers Squibb Company  
Rt. 206 & Province Line Rd.  
Princeton, NJ 08543

**BACKGROUND OF THE ASSIGNMENT**

INVENTOR has conceived a certain new and useful invention disclosed in a United States patent application titled "OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION."

ASSIGNEE desires to acquire the entire right, title and interest in the invention and with respect to any Letters Patent or grant of rights equivalent thereto that may be granted with respect to the invention in both the United States and in all foreign countries.

**THE PARTIES AGREE AS FOLLOWS:**

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the undersigned INVENTOR hereby sells, assigns, and transfers to Bristol-Myers Squibb Company, a corporation, the entire right, title, and interest in the above-identified patent

application executed concurrently herewith and to all divisional, continuing, substitute, renewal, reissue, and all other applications for patent or the legal equivalent thereof which have been or may be filed in the United States and all countries foreign to the United States relating to any subject matter disclosed by the above-identified patent application and hereby authorizes the Commissioner of Patents and Trademarks to issue such Letters Patent to ASSIGNEE for the sole use of ASSIGNEE, its successors, or assigns.

Specifically, ASSIGNEE is hereby authorized to apply for patents relating to the invention in its own name in countries where such procedure is proper; to claim the benefit of, file, and prosecute applications relating to the invention under any international conventions or treaties, if applicable. INVENTOR agrees to execute applications relating to the invention in those countries and under those international conventions or treaties, if applicable, where it is necessary that the same be executed by the inventors, and to execute assignments of such applications and the resulting grant of patent rights or equivalents thereof to ASSIGNEE as well as all other necessary papers in relation to such applications and Letters Patent.

The INVENTOR further agrees, at the request and expense of ASSIGNEE, to:

execute all divisional, continuing, substitute, renewal, reissue, and any other documents relating thereto;

execute all rightful oaths, declarations, assignments, powers of attorney, and other papers;

communicate to the ASSIGNEE all facts and provide to the ASSIGNEE all documents and things known to the undersigned relating to the above-referenced Application for United States Letters Patent;

testify as to the same in any interference, litigation, or other proceeding relating to the above-referenced application for United States Letters Patent; and

in general, do everything reasonably possible which the ASSIGNEE shall consider desirable for vesting title to such Application for United States Letters Patent in the ASSIGNEE, and for securing, maintaining, defending, or enforcing valid and enforceable patent protection therefor.


The INVENTOR acknowledges that the sale, assignment, and transfer of rights and property set forth herein is and shall be irrevocable and binding upon the heirs, assigns, representatives and successors of each undersigned INVENTOR and extends to the successors, assigns, and nominees of the ASSIGNEE.

**POWER OF ATTORNEY**

In the event the ASSIGNEE is unable to secure INVENTOR'S signature on any document necessary to apply for, prosecute, obtain, or enforce any patent, copyright, or other right or protection relating to any invention, whether due to mental or physical incapacity or other cause, INVENTOR hereby irrevocably designates and appoints the ASSIGNEE and each of its duly authorized officers and agents as his or her agent and attorney-in-fact, to act for and in his or her behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and enforcement of patents, copyrights, or other rights or protections with the same force and effect as if executed and delivered by the INVENTOR.

H&H Ref. No. 103135.0239  
Roche Ref. No. P34850-US-1

Signed on NOV 16 2018, 2018.

  
Richard E. Olson